Xinjiang Medical University

SHANGHAI, Dec. 11, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced that Shanghai Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), of which Zhongchao consolidates the operations and financial results through a series of contractual arrangements, has renewed its service agreement (the "Agreement") with Beijing Public Health Foundation ("BPHF"), a non-profit organization dedicated to enhancing Chinese citizens' health through public welfare initiatives and aid programs. Pursuant to the Agreement, Zhongxin and BPHF extended its partnership to work together on a patient aid project (the "Project") to provide medication assistance services for cancer patients. The Project offers free Doxorubicin Hydrochloride Liposome Injections to low-income patients with breast cancer, lymphoma, Kaposi's sarcoma, ovarian cancer, osteosarcoma, and myeloma based on their needs. The Project aims to ensure patients to have longer lasting and more effective medical treatments with less financial burden. The Project operates through over 300 hospitals and 100 pharmacies, where qualified cancer patients after an assessment can receive their medications for free. To date, the Project has been in operation for three years, serving over 6,000 patients and donating more than 22,000 doses of medication. Under the supervision and guidance of BPHF, Zhongxin, leveraging its self-developed patient assistance program technical service platform, is responsible for providing staff with training and daily operation management, maintaining the project website, management for patients, and monitoring and analyzing project progress. These efforts aim to standardize the workflow and enhance the operational efficiency of the Project. Additionally, the platform also performs information management for Project participants, such as hospitals and pharmacies, to improve operational efficiency and accuracy. With the rising incidence of cancer and prolonged life expectancy brought by new technologies, the cost of innovative medications and long-term treatments has intensified financial burden on patients. Zhongchao believes that the Project encourages and supports patients in need to adhere to sustained treatments with significant therapeutic effects and less financial burden on families. Zhongchao remains committed to leveraging its service capabilities and experience in enhancing treatment efficiency and quality of life for cancer patients. About Zhongchao Inc. Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It consolidates the financial results of a variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the "PRC operating entities") through a series of contractual arrangements. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at . Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: At the Company: Pei Xu, CFO Email: [email protected] Phone: +86 13901629242 Investor Relations: Sherry Zheng Weitian Group LLC Email: [email protected] Phone: +1 718-213-7386 SOURCE Zhongchao Inc.

SHANGHAI, Sept. 25, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced the introduction of its Patient-Reported Outcome (PRO) -based symptom management model. This model is geared toward aiding the recovery of lung cancer patients and enhancing their life quality. Many lung cancer patients are grappling with a multitude of symptoms throughout their treatment process, including but not limited to fatigue, reduced appetite, nausea, and approximately 34 other symptoms. These symptoms can lead to emotional turmoil towards patients, manifesting as anxiety or depression, severely impacting patients' life quality and their overall recovery process. The PRO-based symptom management method prioritizes genuine feedbacks from patients about their health conditions, which aids in accurately identifying underlying health concerns and enhancing overall well-being. A study published in the "Journal of Clinical Oncology" in 2022 also highlighted that a PRO-driven model integrating proactive Symptom Monitoring, Alerting, and Response System can significantly reduce post-discharge symptoms and complications in lung cancer patients, accelerate their post-operative recovery and receive high satisfaction from patients. Zhongchao's existing patient management services already features a comprehensive range of offerings for lung cancer patients. The expert-led seminars could guide patients and offer direct engagement through mobile applications to answer their queries virtually. The seminars ensure patients fully understand their treatment journey and can enhance their adherence to treatment protocols. Zhongchao also provides a suite of resources through mobile applications, including, among the others, educational contents, disease follow-up visits, lifestyle advice, drug aids information and other support services. To facilitate efficient and one-on-one patient communications, Zhongchao has established robust follow-up channels through various platforms such as telephones, WeChat, and text messages, staffed by dedicated disease management specialists. Unlike the existing patient management services, which focus primarily on medical aspects such as Duration of Therapy, the newly introduced PRO-based management model shifts the focus towards patients' own experiences and feelings about their health, bringing a fresh perspective into patient care. By actively collecting and analyzing patient feedbacks on physical symptoms, emotional states, self-perceptions and other PRO data, the Company is able to continually refine its management methods, aiming to enhance the living standards and well-being of lung cancer patients. Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "We believe that PRO-based symptom management method provides an invaluable way to detect lung cancer patients' underlying health issues accurately and comprehensively, assist clinical decisions and improve the quality of care for our lung cancer patients. At Zhongchao, we are continually refining our approaches to patient management services, aiming to achieve meaningful and lasting impacts on the lives of cancer patients." About Zhongchao Inc. Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It consolidates the financial results of a variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the "PRC operating entities") through a series of contractual arrangements. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at . Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: At the Company: Pei Xu, CFO Email: [email protected] Phone: +86 13901629242 Investor Relations: Sherry Zheng Weitian Group LLC Email: [email protected] Phone: +1 718-213-7386 SOURCE Zhongchao Inc.

SHANGHAI, Aug. 24, 2023 /PRNewswire/ -- Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services for patients with cancer and other major diseases, today announced it has achieved a milestone of serving over 10,000 breast cancer patients in China with comprehensive disease management services since 2021. By offering disease management services, Zhongchao aims to ensure effective medical treatments while reducing financial hardships and enhance the overall quality of life for these patients. Recently published statistics indicated a great need for disease management for breast cancer patients in China. The 2022 China Breast Cancer Follow-up and Health Management Guidelines highlighted the number of approximately 420,000 new breast cancer diagnoses in China in 2022, which ranked first and represented almost 20% of all malignant tumors diagnosed in women in China. As cure rates of breast cancer increased and the average survival time for is prolonged, there is an evident rising demand for life-long comprehensive disease management. Additionally, financial challenges arising from breast cancer treatment further called for such disease management. The 2022 China Breast Cancer Patient Quality of Life White Paper sheds light on the economic strains: breast cancer patients are burdened with an average treatment expense of RMB206,000, with out-of-pocket costs reaching up to RBM111,000 based on the questionnaires completed by breast cancer patients. Particularly, over 64% of these patients had households income of less than RBM100,000. Zhongchao initiated its disease management services back in 2021 to alleviate financial burdens and facilitate treatment process for eligible breast cancer patients. In collaboration with multiple hospitals, pharmacies, pharmaceutical enterprises, non-profit organizations and insurance companies, Zhongchao provides various management services, including but not limited to, drug aids, disease follow-up visits, medication management, and cancer education. The Company's dedicated service team, accessible via a dedicated hotline, offers patient inquiries, medication assistance, medication usage and experience tracking, and sustained follow-up visits and management. From 2021 to 2023, Zhongchao's concerted efforts have aided over 10,000 breast cancer patients. Zhongchao believes its comprehensive disease management services for breast cancer patients alleviates financial burdens, promotes patient education and engagement, and contributes to optimal treatment results and life quality. Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "In our position as a digital platform in healthcare and patient services, we have consistently prioritized holistic patient support, from financial assistance to intensive disease management. From 2021, we have consistently expanded our services to serve more types of cancer treatment, promoting treatment process, and improving patient quality of life. Our unwavering dedication to assisting and supporting breast cancer patients and other major diseases patients in China remains at the forefront of our mission." About Zhongchao Inc. Zhongchao Inc. is an offshore holding company incorporated in the Cayman Islands. It consolidates the financial results of a variable interest entity, Zhongchao Medical Technology (Shanghai) Limited, and its subsidiaries (the "PRC operating entities") through a series of contractual arrangements. Zhongchao Inc. is a platform-based internet technology company offering services to patients with oncology and other major diseases. The PRC operating entities provide online healthcare information, professional training and educational services to healthcare professionals under their "MDMOOC" platform (), offer patient management services in the professional field of tumor and rare diseases through Zhongxin, offer internet healthcare services through Zhixun Internet Hospital, and pharmaceutical services through Xinjiang Medical and operate an online information platform, Sunshine Health Forums, to general public. More information about the Company can be found at its investor relations website at . Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the professional training and educational services market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC, the length and severity of the recent coronavirus outbreak, including its impacts across our business and operations. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at . The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: At the Company: Pei Xu, CFO Email: [email protected] Phone: +86 13901629242 Investor Relations: Sherry Zheng Weitian Group LLC Email: [email protected] Phone: +1 718-213-7386 SOURCE Zhongchao Inc.